Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05742802 · ClinicalTrials.gov registry record · Phase 3

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,713
Enrollment target
20
Study locations

NCT05742802 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,713 participants, above the 604-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05742802, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,713 participants
Enrollment target
20
Study locations

Study Summary

Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.

Conditions Studied

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • COMBINATION_PRODUCT Placebo
  • COMBINATION_PRODUCT Tozorakimab 1
  • COMBINATION_PRODUCT Tozorakimab 2

Study Locations (20)

Florida

  • Research Site - Boynton Beach
  • Research Site - Cape Coral
  • Research Site - Ormond Beach
  • Research Site - Pensacola
  • Research Site - Plantation
  • Research Site - Tampa
  • Research Site - Winter Park

California

  • Research Site - Lincoln
  • Research Site - Newport Beach
  • Research Site - Northridge

Illinois

  • Research Site - Evergreen Park
  • Research Site - Normal

Louisiana

  • Research Site - Baton Rouge
  • Research Site - Zachary

Alabama

  • Research Site - Sheffield

Arizona

  • Research Site - Tempe

Indiana

  • Research Site - Greenwood

Kansas

  • Research Site - Kansas City

Trial Details

FieldValue
Enrollment Target 1,713 participants
Start Date 2023-03-06
Est. Completion 2026-05-28
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05742802

The ClinicalTrials.gov registry entry for NCT05742802 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,713 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 604-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (184% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT05742802 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT05742802 about?

NCT05742802 is a clinical study titled "Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).". Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.

What is the current status of trial NCT05742802?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,713 participants. The study started on 2023-03-06. Estimated completion is 2026-05-28.

What conditions does trial NCT05742802 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).

What interventions are being tested in trial NCT05742802?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Tozorakimab 1 (COMBINATION_PRODUCT), Tozorakimab 2 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05742802?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05742802 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease (COPD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.